Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Visual Disorders in Parkinson Disease

  • Neurologic Ophthalmology and Otology (RK Shin and DR Gold, Section Editors)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of review

This article discusses visual disorders in both Parkinson disease (PD) and other Parkinsonian disorders. It is organized largely by the anatomical site of pathology and emphasizes practical treatments. Targeted treatment options include medications, surgery, occupational, and physical therapies as well as optical aids.

Recent findings

The causes of visual complaints in Parkinson disease and other similar disorders are being more clearly identified. A new medication approved specifically to treat hallucinations in PD now is available. There is increased understanding of the important role that an ophthalmologist can play in the care of these patients. Finally, research and therapeutic development are unmet needs in accessing and treating visual complaints in PD and Parkinsonian disorders.

Summary

A better understanding of Parkinson-related visual complaints and of available treatment options is important to optimize patient safety and quality of life. Vision impairment leads to difficulties in many common activities including reading, ambulating, and driving. Falls and injuries, made more likely because of impaired vision, result in an early loss of independence. Awareness of the problem, patient education, ophthalmologic care, selected therapeutics, physical therapy, and occupational therapy are crucial to maximizing quality of life in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest. 2006;116(7):1744–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson’s disease. Brain. 2016;139(11):2827–43.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wolters E. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S6–12.

    Article  PubMed  Google Scholar 

  4. Urwyler P, Nef T, Killen A, Collerton D, Thomas A, Burn D, et al. Visual complaints and visual hallucinations in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(3):318–22.

    Article  PubMed  Google Scholar 

  5. •• Schindlbeck KA, Schonfeld S, Naumann W, Friedrich DJ, Maier A, Rewitzer C, et al. Characterization of diplopia in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;45:1–6. A careful study of non-demented PD patients exploring the incidence and character of diplopia, one of the most frequently observed visual symptoms of PD.

    Article  PubMed  Google Scholar 

  6. •• Ekker MS, Janssen S, Seppi K, Poewe W, de Vries NM, Theelen T, et al. Ocular and visual disorders in Parkinson’s disease: common but frequently overlooked. Parkinsonism Relat Disord. 2017;40:1–10. Excellent review of visual system abnormalities in PD with recommendations for treatment. This review includes useful diagrams and charts and covers how treatment of PD may impair visual function.

    Article  PubMed  Google Scholar 

  7. Domenici L, Trimarchi C, Piccolino M, Fiorentini A, Maffei L. Dopaminergic drugs improve human visual contrast sensitivity. Hum Neurobiol. 1985;4(3):195–7.

    PubMed  CAS  Google Scholar 

  8. Bhaskar PA, Vanchilingam S, Bhaskar EA, Devaprabhu A, Ganesan RA. Effect of L-dopa on visual evoked potential in patients with Parkinson’s disease. Neurology. 1986;36(8):1119–21.

    Article  PubMed  CAS  Google Scholar 

  9. Bodis-Wollner I. Visual electrophysiology in Parkinson’s disease: PERG, VEP and visual P300. Clin Electroencephalogr. 1997;28(3):143–7.

    Article  PubMed  CAS  Google Scholar 

  10. Tolosa E, Compta Y. Dystonia in Parkinson’s disease. J Neurol. 2006;253(Suppl 7):VII7–13.

    PubMed  Google Scholar 

  11. Doherty KM, van de Warrenburg BP, Peralta MC, Silveira-Moriyama L, Azulay JP, Gershanik OS, et al. Postural deformities in Parkinson’s disease. Lancet Neurol. 2011;10(6):538–49.

    Article  PubMed  Google Scholar 

  12. Chieng LO, Madhavan K, Wang MY. Deep brain stimulation as a treatment for Parkinson’s disease related camptocormia. J Clin Neurosci. 2015;22(10):1555–61.

    Article  PubMed  Google Scholar 

  13. Green KE, Rastall D, Eggenberger E. Treatment of blepharospasm/hemifacial spasm. Curr Treat Options Neurol. 2017;19(11):41.

    Article  PubMed  Google Scholar 

  14. Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry. 1995;59(3):309–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Goldstein JE, Cogan DG. Apraxia of lid opening. Arch Ophthalmol. 1965;73:155–9.

    Article  PubMed  CAS  Google Scholar 

  16. Piccione F, Mancini E, Tonin P, Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil. 1997;78(5):525–9.

    Article  PubMed  CAS  Google Scholar 

  17. Krack P, Marion MH. “Apraxia of lid opening,” a focal eyelid dystonia: clinical study of 32 patients. Mov Disord. 1994;9(6):610–5.

    Article  PubMed  CAS  Google Scholar 

  18. Rana AQ, Shah R. Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment. Acta Neurol Belg. 2012;112(1):95–6.

    Article  PubMed  Google Scholar 

  19. Hanuska J, Bonnet C, Rusz J, Sieger T, Jech R, Rivaud-Pechoux S, et al. Fast vergence eye movements are disrupted in Parkinson’s disease: a video-oculography study. Parkinsonism Relat Disord. 2015;21(7):797–9.

    Article  PubMed  Google Scholar 

  20. Armstrong RA. Visual dysfunction in Parkinson’s disease. Int Rev Neurobiol. 2017;134:921–46.

    Article  PubMed  Google Scholar 

  21. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophthalmologic features of Parkinson’s disease. Neurology. 2004;62(2):177–80.

    Article  PubMed  CAS  Google Scholar 

  22. Nebe A, Ebersbach G. Selective diplopia in Parkinson’s disease: a special subtype of visual hallucination? Mov Disord. 2007;22(8):1175–8.

    Article  PubMed  Google Scholar 

  23. Shibasaki H, Tsuji S, Kuroiwa Y. Oculomotor abnormalities in Parkinson’s disease. Arch Neurol. 1979;36(6):360–4.

    Article  PubMed  CAS  Google Scholar 

  24. Ming W, Palidis DJ, Spering M, McKeown MJ. Visual contrast sensitivity in early-stage Parkinson’s disease. Invest Ophthalmol Vis Sci. 2016;57(13):5696–704.

    Article  PubMed  Google Scholar 

  25. Leigh RJ, Zee DS. The neurology of eye movements. 3rd ed. New York: Oxford University Press; 1999. x, 646 p. p.

  26. • Vintonyak O, Gorges M, Muller HP, Pinkhardt EH, Ludolph AC, Huppertz HJ, et al. Patterns of eye movement impairment correlate with regional brain atrophy in neurodegenerative parkinsonism. Neurodegener Dis. 2017;17(4–5):117–26. Interesting study correlating patents of brain atrophy with type of Parkinsonism.

    Article  PubMed  Google Scholar 

  27. Friedman DI, Jankovic J, McCrary JA 3rd. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol. 1992;12(2):104–9.

    PubMed  Google Scholar 

  28. •• Termsarasab P, Thammongkolchai T, Rucker JC, Frucht SJ. The diagnostic value of saccades in movement disorder patients: a practical guide and review. J Clin Mov Disord. 2015;2:14. Excellent review on using saccadic dysfunction as an aid in diagnosing movement disorders.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Pinkhardt EH, Kassubek J. Ocular motor abnormalities in Parkinsonian syndromes. Parkinsonism Relat Disord. 2011;17(4):223–30.

    Article  PubMed  Google Scholar 

  30. Gazulla J, Benavente MI. Improvements in the symptoms of olivopontocerebellar atrophy with gabapentin. Rev Neurol. 2005;40(5):285–8.

    PubMed  CAS  Google Scholar 

  31. Armstrong RA. Visual signs and symptoms of multiple system atrophy. Clin Exp Optom. 2014;97(6):483–91.

    Article  PubMed  Google Scholar 

  32. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain. 1994;117(Pt 5):1183–96.

    Article  PubMed  Google Scholar 

  33. Bares M, Brazdil M, Kanovsky P, Jurak P, Daniel P, Kukleta M, et al. The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinsonian patients. Parkinsonism Relat Disord. 2003;9(3):139–44.

    Article  PubMed  Google Scholar 

  34. Almer Z, Klein KS, Marsh L, Gerstenhaber M, Repka MX. Ocular motor and sensory function in Parkinson’s disease. Ophthalmology. 2012;119(1):178–82.

    Article  PubMed  Google Scholar 

  35. Racette BA, Gokden MS, Tychsen LS, Perlmutter JS. Convergence insufficiency in idiopathic Parkinson’s disease responsive to levodopa. Strabismus. 1999;7(3):169–74.

    Article  PubMed  CAS  Google Scholar 

  36. Nilsson MH, Patel M, Rehncrona S, Magnusson M, Fransson PA. Subthalamic deep brain stimulation improves smooth pursuit and saccade performance in patients with Parkinson’s disease. J Neuroeng Rehabil. 2013;10:33.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lowrey BR, Wong L. Progressive supranuclear palsy. Clin Eye Vis Care. 2000;12(3–4):171–5.

    Article  PubMed  CAS  Google Scholar 

  38. Weisz RR, Richer SP, Jordan M, Tucker EG. Case report: prismatic redirection of vision for progressive supranuclear palsy. J Am Optom Assoc. 1991;62(7):537–9.

    PubMed  CAS  Google Scholar 

  39. Peli E. Fitting peripheral prisms for hemianopia (video). 2017 North American Neuro-Ophthalmology Society Annual Meeting, NOVEL: Neuro-ophthalmology Virtual Education Library, NANOS Annual Meeting, http://novel.utah.edu/collection/NAM/toc/; https://collections.lib.utah.edu/details?id=1278135; 10/27/2017. Accessed 2/15/2018. 2017

  40. Rucker JC, Phillips PH. Efferent vision therapy. J Neuroophthalmol. 2017;

  41. Zampieri C, Di Fabio RP. Improvement of gaze control after balance and eye movement training in patients with progressive supranuclear palsy: a quasi-randomized controlled trial. Arch Phys Med Rehabil. 2009;90(2):263–70.

    Article  PubMed  Google Scholar 

  42. Barrett BT. A critical evaluation of the evidence supporting the practice of behavioural vision therapy. Ophthalmic Physiol Opt. 2009;29(1):4–25.

    Article  PubMed  Google Scholar 

  43. Taylor D, Hoyt CS. Pediatric ophthalmology and strabismus, vol. xvii. 3rd ed. London: Elsevier Saunders; 2005. 1170 p. p

  44. Rosini F, Federighi P, Pretegiani E, Piu P, Leigh RJ, Serra A, et al. Ocular-motor profile and effects of memantine in a familial form of adult cerebellar ataxia with slow saccades and square wave saccadic intrusions. PLoS One. 2013;8(7):e69522.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Shery T, Proudlock FA, Sarvananthan N, McLean RJ, Gottlob I. The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. Br J Ophthalmol. 2006;90(7):839–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Feil K, Claassen J, Bardins S, Teufel J, Krafczyk S, Schneider E, et al. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial. Neurology. 2013;81(13):1152–8.

    Article  PubMed  CAS  Google Scholar 

  47. Strupp M, Schuler O, Krafczyk S, Jahn K, Schautzer F, Buttner U, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61(2):165–70.

    Article  PubMed  CAS  Google Scholar 

  48. Kalla R, Teufel J, Feil K, Muth C, Strupp M. Update on the pharmacotherapy of cerebellar and central vestibular disorders. J Neurol. 2016;263(Suppl 1):S24–9.

    Article  PubMed  CAS  Google Scholar 

  49. Young YH, Huang TW. Role of clonazepam in the treatment of idiopathic downbeat nystagmus. Laryngoscope. 2001;111(8):1490–3.

    Article  PubMed  CAS  Google Scholar 

  50. Bologna M, Agostino R, Gregori B, Belvisi D, Ottaviani D, Colosimo C, et al. Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy. Brain. 2009;132(Pt 2):502–10.

    PubMed  Google Scholar 

  51. Armstrong RA. Visual signs and symptoms of corticobasal degeneration. Clin Exp Optom. 2016;99(6):498–506.

    Article  PubMed  Google Scholar 

  52. Demirci S, Gunes A, Koyuncuoglu HR, Tok L, Tok O. Evaluation of corneal parameters in patients with Parkinson’s disease. Neurol Sci. 2016;37(8):1247–52.

    Article  PubMed  Google Scholar 

  53. •• Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K. Ophthalmological features of Parkinson disease. Med Sci Monit. 2014;20:2243–9. Report on 100 non-demented PD patients and the incidence of ophthalmologic changes.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Misra SL, Kersten HM, Roxburgh RH, Danesh-Meyer HV, McGhee CN. Corneal nerve microstructure in Parkinson’s disease. J Clin Neurosci. 2017;39:53–8.

    Article  PubMed  Google Scholar 

  55. Bologna M, Fasano A, Modugno N, Fabbrini G, Berardelli A. Effects of subthalamic nucleus deep brain stimulation and L-DOPA on blinking in Parkinson’s disease. Exp Neurol. 2012;235(1):265–72.

    Article  PubMed  CAS  Google Scholar 

  56. • van der Westhuizen L, Pucker AD. Over the counter (OTC) artificial tear drops for dry eye syndrome: a Cochrane review summary. Int J Nurs Stud. 2017;71:153–4. Cochrane review that finds utility in using eye drops for dry eye symptoms and illustrates the need for more research on this very basic treatment option.

    Article  PubMed  Google Scholar 

  57. Micieli G, Tassorelli C, Martignoni E, Pacchetti C, Bruggi P, Magri M, et al. Disordered pupil reactivity in Parkinson’s disease. Clin Auton Res. 1991;1(1):55–8.

    Article  PubMed  CAS  Google Scholar 

  58. Bremner F, Smith S. Pupil findings in a consecutive series of 150 patients with generalised autonomic neuropathy. J Neurol Neurosurg Psychiatry. 2006;77(10):1163–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. Alpha-synuclein in the inner retina in parkinson disease. Ann Neurol. 2014;75(6):964–6.

    Article  PubMed  CAS  Google Scholar 

  60. Kromer R, Buhmann C, Hidding U, Keseru M, Keseru D, Hassenstein A, et al. Evaluation of retinal vessel morphology in patients with Parkinson’s disease using optical coherence tomography. PLoS. 2016;11(8):e0161136.

    Article  CAS  Google Scholar 

  61. Stemplewitz B, Kromer R, Vettorazzi E, Hidding U, Frings A, Buhmann C. Retinal degeneration in progressive supranuclear palsy measured by optical coherence tomography and scanning laser polarimetry. Sci Rep. 2017;7(1):5357.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Witkovsky P. Dopamine and retinal function. Doc Ophthalmol. 2004;108(1):17–40.

    Article  PubMed  Google Scholar 

  63. Polo V, Satue M, Rodrigo MJ, Otin S, Alarcia R, Bambo MP, et al. Visual dysfunction and its correlation with retinal changes in patients with Parkinson’s disease: an observational cross-sectional study. BMJ Open. 2016;6(5):e009658.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Rodnitzky RL. Visual dysfunction in Parkinson’s disease. Clin Neurosci. 1998;5(2):102–6.

    PubMed  CAS  Google Scholar 

  65. Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer’s disease and Parkinson’s disease. Am J Ophthalmol. 2002;133(1):135–7.

    Article  PubMed  Google Scholar 

  66. Lin TP, Rigby H, Adler JS, Hentz JG, Balcer LJ, Galetta SL, et al. Abnormal visual contrast acuity in Parkinson’s disease. J Parkinsons Dis. 2015;5(1):125–30.

    PubMed  Google Scholar 

  67. Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett. 1982;33(3):305–10.

    Article  PubMed  CAS  Google Scholar 

  68. Njie-Mbye YF, Kulkarni-Chitnis M, Opere CA, Barrett A, Ohia SE. Lipid peroxidation: pathophysiological and pharmacological implications in the eye. Front Physiol. 2013;4:366.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Nucci C, Martucci A, Cesareo M, Garaci F, Morrone LA, Russo R, et al. Links among glaucoma, neurodegenerative, and vascular diseases of the central nervous system. Prog Brain Res. 2015;221:49–65.

    Article  PubMed  Google Scholar 

  70. Rieger G. Improvement of contrast sensitivity with yellow filter glasses. Can J Ophthalmol. 1992;27(3):137–8.

    PubMed  CAS  Google Scholar 

  71. Antal A, Bandini F, Keri S, Bodis-Wollner I. Visuo-cognitive dysfunctions in Parkinson’s disease. Clin Neurosci. 1998;5(2):147–52.

    PubMed  CAS  Google Scholar 

  72. Arrigo A, Calamuneri A, Milardi D, Mormina E, Rania L, Postorino E, et al. Visual system involvement in patients with newly diagnosed Parkinson disease. Radiology. 2017;285(3):885–95.

    Article  PubMed  Google Scholar 

  73. Sun L, Zhang H, Gu Z, Cao M, Li D, Chan P. Stereopsis impairment is associated with decreased color perception and worse motor performance in Parkinson’s disease. Eur J Med Res. 2014;19:29.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. McDowell SA, Harris J. Irrelevant peripheral visual stimuli impair manual reaction times in Parkinson’s disease. Vis Res. 1997;37(24):3549–58.

    Article  PubMed  CAS  Google Scholar 

  75. Formaglio M, Krolak-Salmon P, Tilikete C, Bernard M, Croisile B, Vighetto A. Homonymous hemianopia and posterior cortical atrophy. Rev Neurol (Paris). 2009;165(3):256–62.

    Article  CAS  Google Scholar 

  76. Rey GJ, Tomer R, Levin BE, Sanchez-Ramos J, Bowen B, Bruce JH. Psychiatric symptoms, atypical dementia, and left visual field inattention in corticobasal ganglionic degeneration. Mov Disord. 1995;10(1):106–10.

    Article  PubMed  CAS  Google Scholar 

  77. Norton DJ, Jaywant A, Gallart-Palau X, Cronin-Golomb A. Normal discrimination of spatial frequency and contrast across visual hemifields in left-onset Parkinson’s disease: evidence against perceptual hemifield biases. Vis Res. 2015;107:94–100.

    Article  PubMed  Google Scholar 

  78. Davidsdottir S, Cronin-Golomb A, Lee A. Visual and spatial symptoms in Parkinson’s disease. Vis Res. 2005;45(10):1285–96.

    Article  PubMed  Google Scholar 

  79. Sprengelmeyer R, Young AW, Mahn K, Schroeder U, Woitalla D, Buttner T, et al. Facial expression recognition in people with medicated and unmedicated Parkinson’s disease. Neuropsychologia. 2003;41(8):1047–57.

    Article  PubMed  CAS  Google Scholar 

  80. Yu CY, Lee T, Shariati MA, Santini V, Poston K, Liao YJ. Abnormal eye movement behavior during reading in Parkinson’s disease. Parkinsonism Relat Disord. 2016;32:130–2.

    Article  PubMed  Google Scholar 

  81. Alvarez FJ. Parkinson’s disease, antiparkinson medicines, and driving. Expert Rev Neurother. 2016;16(9):1023–32.

    Article  PubMed  CAS  Google Scholar 

  82. Devos H, Ranchet M, Emmanuel Akinwuntan A, Uc EY. Establishing an evidence-base framework for driving rehabilitation in Parkinson’s disease: a systematic review of on-road driving studies. NeuroRehabilitation. 2015;37(1):35–52.

    Article  PubMed  Google Scholar 

  83. • Urwyler P, Nef T, Muri R, Archibald N, Makin SM, Collerton D, et al. Visual hallucinations in eye disease and Lewy body disease. Am J Geriatr Psychiatry. 2016;24(5):350–8. Interesting study on the character of hallucinations in DLB and PD and how it varies from that seen in eye disease.

    Article  PubMed  Google Scholar 

  84. Gibson G, Mottram PG, Burn DJ, Hindle JV, Landau S, Samuel M, et al. Frequency, prevalence, incidence and risk factors associated with visual hallucinations in a sample of patients with Parkinson’s disease: a longitudinal 4-year study. Int J Geriatr Psychiatry. 2013;28(6):626–31.

    Article  PubMed  CAS  Google Scholar 

  85. Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009;5(6):331–42.

    Article  PubMed  CAS  Google Scholar 

  86. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26(13):2387–95.

    Article  PubMed  Google Scholar 

  87. Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2006;19(1):36–40.

    Article  PubMed  Google Scholar 

  88. Poewe W. When a Parkinson’s disease patient starts to hallucinate. Pract Neurol. 2008;8(4):238–41.

    Article  PubMed  Google Scholar 

  89. • Panchal SC, Ondo WG. Treating hallucinations and delusions associated with Parkinson’s disease psychosis. Curr Psychiatry Rep. 2018;20(1):3. Very recent review of the current state of therapeutic options in treating PD hallucinations.

    Article  PubMed  Google Scholar 

  90. Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson’s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis. 2016;50(3):733–40.

    Article  PubMed  CAS  Google Scholar 

  91. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21(11):1899–907.

    Article  PubMed  Google Scholar 

  92. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr Med Res Opin. 2002;18(5):258–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Maryland School of Medicine, 110 South Paca Street 3rd Floor, Baltimore, MD, 21201, USA

    Joseph Savitt MD, PhD

  2. Department of Ophthalmology, University of Maryland School of Medicine, Baltimore, MD, USA

    Michaela Mathews MD

Authors
  1. Joseph Savitt MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michaela Mathews MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Savitt MD, PhD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Neurologic Ophthalmology and Otology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Savitt, J., Mathews, M. Treatment of Visual Disorders in Parkinson Disease. Curr Treat Options Neurol 20, 30 (2018). https://doi.org/10.1007/s11940-018-0519-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-018-0519-0

Keywords

Search

Navigation